apn01
Recombinant proteinexperimental
Clinical trial activity
3 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Apr 1, 2009 (NCT00886353)
Timeline
Indications
Mechanism of action
- Angiotensin-converting enzyme 2INHIBITOR
ACE2 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- apn01
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04924660 | Phase 2/Phase 3 (Phase 3) | Jul 15, 2021 | National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), Vanderbilt University |
| NCT04335136 | Phase 2 | Apr 30, 2020 | Apeiron Biologics, University of Copenhagen |
| NCT00886353 | Phase 1 | Apr 1, 2009 | Aperion Biologics, University of Bern |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Apeiron Biologics | For profit | 1 | 1 | 1 | 2020 |
| Aperion Biologics | For profit | 1 | 1 | 1 | 2009 |
| National Heart, Lung, and Blood Institute (NHLBI) | Government | 1 | 0 | 1 | 2021 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2021 |
| University of Bern | Academic/Hospital | 1 | 0 | 1 | 2009 |
| University of Copenhagen | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Vanderbilt University | Academic/Hospital | 1 | 1 | 1 | 2021 |
7 organizations
Page 1 / 1